• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    7/24/24 2:20:14 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRUS alert in real time by email
    SC 13G/A 1 tm2419961d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    MERUS N.V.

    (Name of Issuer)

     

    Common Shares, nominal value €0.09 per share

    (Title of Class of Securities)

     

    N5749R100

    (CUSIP Number)

     

    June 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

      13G (Amendment No. 1) Page 2 of 5 Pages

             
    1.  

    NAMES OF REPORTING PERSONS

     

    Incyte Corporation

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    ¨
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
       

             
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5.   SOLE VOTING POWER
     
    1,008,076
      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    1,008,076
      8.   SHARED DISPOSITIVE POWER
     
    0

             
    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,008,076

       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨
       
    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.5%*

       
    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    CO

       
       

     

    *See footnotes to Item 4 below.

       

     

     

     

     

      13G (Amendment No. 1) Page 3 of 5 Pages

     

    Item 1(a) Name of Issuer:
       
      Merus N.V. (“Merus”)
       
    Item 1(b) Address of Issuer’s Principal Executive Offices:
       
      Upsalalaan 17, 3584 CT Utrecht, The Netherlands
       
    Item 2(a) Name of Person Filing:
       
      Incyte Corporation (“Incyte”)
       
    Item 2(b) Address of the Principal Business Office or, if none, Residence:
       
      1801 Augustine Cut-Off, Wilmington, DE 19803
       
    Item 2(c) Citizenship:
       
      Delaware
       
    Item 2(d) Title of Class of Securities:
       
      common shares, nominal value €0.09 per share (“Common Shares”)
       
    Item 2(e) CUSIP Number:
       
      N5749R100
       
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable
       
    Item 4. Ownership

     

      (a) Amount beneficially owned:  1,008,076 shares
       
      (b) Percent of class:  1.5%(1)
       
      (c) Number of shares as to which the person has: 
       
      (i) Sole power to vote or to direct the vote:  1,008,076 shares
       
      (ii) Shared power to vote or to direct the vote:  0
       
      (iii) Sole power to dispose or to direct the disposition of:  1,008,076 shares (2)
       
      (iv) Shared power to dispose or to direct the disposition of:  0

     

    (1)The ownership percentage of Incyte has been calculated based on a total of 67,370,051 Common Shares outstanding as of May 30, 2024, as disclosed by Merus in its Prospectus Supplement filed pursuant to Rule 424(b)(5) and its Current Report on Form 8-K, both filed with the Securities and Exchange Commission on May 30, 2024.

     

     

     

     

      13G (Amendment No. 1) Page 4 of 5 Pages

     

    Item 5.Ownership of Five Percent or Less of a Class.
      
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.
       
    Item 6.Ownership of More than Five Percent on Behalf of Another Person.
      
      Not applicable
       
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
      
      Not applicable
       
    Item 8.Identification and Classification of Members of the Group.
      
      Not applicable
       
    Item 9.Notice of Dissolution of Group.
      
      Not applicable
       
    Item 10.Certification.
      
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

     

     

      13G (Amendment No. 1) Page 5 of 5 Pages

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: July 24, 2024

     

      INCYTE CORPORATION
         
      By: /s/ Sheila A. Denton
        Sheila A. Denton
        Executive Vice President and
        General Counsel

     

     

     

    Get the next $MRUS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRUS

    DatePrice TargetRatingAnalyst
    2/13/2025$84.00Overweight
    Piper Sandler
    2/7/2025$91.00Overweight
    Wells Fargo
    11/21/2024$73.00Buy
    Goldman
    10/24/2024$72.00Buy
    UBS
    3/28/2024$69.00Buy
    Truist
    3/4/2024$42.00 → $65.00Buy
    Needham
    11/2/2023$45.00Buy
    Canaccord Genuity
    8/21/2023Outperform
    TD Cowen
    More analyst ratings

    $MRUS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 6, 2024 - FDA Roundup: December 6, 2024

    For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

    12/6/24 3:09:02 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Merus with a new price target

    Piper Sandler initiated coverage of Merus with a rating of Overweight and set a new price target of $84.00

    2/13/25 8:09:56 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Merus with a new price target

    Wells Fargo initiated coverage of Merus with a rating of Overweight and set a new price target of $91.00

    2/7/25 8:26:14 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Merus with a new price target

    Goldman initiated coverage of Merus with a rating of Buy and set a new price target of $73.00

    11/21/24 7:35:31 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Merus N.V.

    SCHEDULE 13G/A - Merus N.V. (0001651311) (Subject)

    8/12/25 10:34:26 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Merus N.V.

    10-Q - Merus N.V. (0001651311) (Filer)

    8/5/25 4:01:03 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Merus N.V.

    424B5 - Merus N.V. (0001651311) (Filer)

    6/5/25 6:07:14 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merus to Present at the Canaccord Genuity 45th Annual Growth Conference

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 1:30 p.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event. Ab

    8/6/25 8:00:00 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update

    - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 63% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months - Based on the Company's current operating plan, existing cash, cash equivalents, including successful public offering raising $345M gross proceeds, and marketable securities expected to fund Merus' operations at least into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Tricloni

    8/5/25 4:07:13 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we" and "our"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that the Company granted non-statutory stock options to two new employees as an inducement award outside the Company's 2016 Incentive Award Plan (the "Plan") in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 240,000 shares of its common stock to two new employees. The stock options were granted on August 1, 2025.

    8/4/25 4:01:00 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO & GC Silverman Peter B. exercised 25,000 shares at a strike of $24.43 and sold $1,500,000 worth of shares (25,000 units at $60.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    7/18/25 4:05:09 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO & GC Silverman Peter B. exercised 23,500 shares at a strike of $18.61 and sold $1,292,500 worth of shares (23,500 units at $55.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    7/11/25 4:09:56 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO & GC Silverman Peter B. exercised 34,000 shares at a strike of $18.61 and sold $1,793,840 worth of shares (34,000 units at $52.76) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    6/24/25 4:00:05 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    SC 13G/A - Merus N.V. (0001651311) (Subject)

    11/14/24 4:05:20 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    SC 13G/A - Merus N.V. (0001651311) (Subject)

    11/14/24 1:34:01 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    SC 13G/A - Merus N.V. (0001651311) (Subject)

    11/14/24 8:54:46 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Leadership Updates

    Live Leadership Updates

    View All

    Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development f

    7/1/24 8:00:00 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors. "I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech e

    6/15/23 7:47:06 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr

    1/25/22 4:30:00 PM ET
    $INCY
    $MRUS
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MRUS
    Financials

    Live finance-specific insights

    View All

    Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

    -  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be

    5/22/25 5:30:00 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

    - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced financial results for the first quarter and provided a business update. "We are very muc

    5/7/25 4:11:44 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

    - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting, being held in Chicago, Illinois on May 30- June 3, 202

    4/23/25 10:00:00 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care